Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Sachiyo OnishiMasahiro TajikaTsutomu TanakaKeisaku YamadaTomoyasu KamiyaTetsuya AbeEiji HigakiHironori FujiedaTakuya NagaoYoshitaka InabaKei MuroMasahito ShimizuYasumasa NiwaPublished in: Journal of clinical medicine (2022)
Effects of changes in body composition during neoadjuvant chemotherapy (NAC) on perioperative complications and prognosis are unknown in patients with esophageal squamous cell carcinoma (ESCC). A total of 175 patients who underwent surgery for ESCC in our hospital between 2016 and 2019 were examined. The psoas muscle index (PMI) was calculated from the total psoas muscle area, and the visceral fat mass (VFM) at the umbilical level was measured. We defined body composition change (BCC) group as those with increased VFM of ≥ 3% and decreased PMI of ≥ 3% during NAC. Sarcopenia (S) was defined as PMI < 5.89 (male) and <4.06 (female). Nutritional assessment using the Subjective Global Assessment tool was performed upon admission. The percentages of BCC group, pre-NAC S, and post-NAC S was 32.5%, 79.4%, and 80.0%, respectively. BCC group had significantly more postoperative complications ( p < 0.01) and longer hospital stays ( p = 0.03) than groups pre-NAC S and post-NAC S. Overall survival (OS) analysis using the Cox hazard model showed that stage III ( p < 0.01) and post-NAC S ( p = 0.03) were poor prognostic factors. Changes in body composition during NAC affected perioperative complications and prognosis of patients with ESCC.
Keyphrases
- body composition
- transcription factor
- neoadjuvant chemotherapy
- prognostic factors
- resistance training
- bone mineral density
- genome wide analysis
- locally advanced
- lymph node
- skeletal muscle
- sentinel lymph node
- end stage renal disease
- healthcare
- patients undergoing
- minimally invasive
- cardiac surgery
- chronic kidney disease
- ejection fraction
- squamous cell carcinoma
- radiation therapy
- insulin resistance
- type diabetes
- rectal cancer
- early stage
- coronary artery bypass
- risk factors
- adverse drug
- metabolic syndrome